Karyopharm Therapeutics (KPTI) Cash from Operations Growth (3y) (2015 - 2025)
Karyopharm Therapeutics (KPTI) Cash from Operations Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 16.85% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 52.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 96.08% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -24.76% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.23% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 6.22% |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.90% |
| Sep 30, 2025 | 40.89% |
| Jun 30, 2025 | 18.97% |
| Mar 31, 2025 | 13.00% |
| Dec 31, 2024 | -44.44% |
| Sep 30, 2024 | 6.70% |
| Jun 30, 2024 | 11.61% |
| Mar 31, 2024 | 6.14% |
| Dec 31, 2023 | 15.34% |
| Sep 30, 2023 | 12.65% |
| Jun 30, 2023 | 13.91% |
| Mar 31, 2023 | 25.10% |
| Dec 31, 2022 | 12.07% |
| Sep 30, 2022 | 8.06% |
| Jun 30, 2022 | 10.00% |
| Mar 31, 2022 | 3.86% |
| Dec 31, 2021 | 36.24% |
| Sep 30, 2021 | 14.75% |
| Jun 30, 2021 | -14.00% |
| Mar 31, 2021 | -15.14% |